Purpose: The aim of this study was to show the results of computed tomography (CT)-based dosimetry of intracavitary brachytherapy for cervical cancer.
Materials And Methods: A total of 20 patients with cervical cancer underwent intracavitary brachytherapy with external beam radiation therapy. The prescribed dose of brachytherapy was 6 Gy per fraction to point A. In every fraction a CT scan was performed after applicator insertion and three-dimensional (3D) dosimetry was done. The tumor dose was evaluated using D90 (the minimum dose delivered to 90% of the volume), and the doses of risk organs were evaluated using D2cc (the minimum dose in the most irradiated 2 cm3 of the volume).
Results: The mean D90 for the clinical target volume (CTV) was 7.0 Gy (range 4.8-9.8 Gy). There was a negative correlation between the volume and the D90 for the CTV. The mean D2cc doses for the rectum and bladder were 6.0 Gy (range 3.9-9.0 Gy) and 6.5 Gy 5 Gy 2.9-9.0 Gy), respectively.
Conclusion: CT-based 3D dosimetry of intracavitary brachytherapy for cervical cancer was useful for evaluating the doses of the CTV and the organs at risk. In cases with a large CTV, CTV D90 was often lower than the point A dose, and modulation of the prescribed dose might have to be considered.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s11604-010-0504-3 | DOI Listing |
EJNMMI Radiopharm Chem
December 2024
The Hevesy Laboratory, DTU Health Technology, Frederiksborgvej 399, 4000, Roskilde, Denmark.
Background: Brachytherapy (BT) is routinely used in the treatment of various cancers. Current BT relies on the placement of large sources of radioactivity at the tumor site, requiring applicators that may cause local traumas and lesions. Further, they suffer from inflexibility in where they can be placed and some sources reside permanently in the body, causing potential long-term discomfort.
View Article and Find Full Text PDFProstate Int
December 2024
Department of Urology, Keio University, School of Medicine, Tokyo, Japan.
Introduction: Adverse events, such as erectile dysfunction (ED) and lower urinary tract symptoms (LUTS), are significant concerns in prostate cancer (PCa) patients treated with Iodine 125 (I-125) low-dose rate (LDR) prostate brachytherapy (PB). Alpha antagonists and phosphodiesterase-5 inhibitors are used to manage these events. The present study compared the efficacy of low-dose tadalafil with that of tamsulosin for concomitant ED and LUTS in PCa patients treated with I-125 LDR PB.
View Article and Find Full Text PDFBrachytherapy
December 2024
Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, Tamil Nadu, India.
Radiother Oncol
December 2024
Medical Physics Unit, IRCCS, Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Italy. Electronic address:
Purpose: This study aims to investigate and compare High Dose Rate Brachytherapy (HDR-BT) with Helical Tomotherapy (HT) treatment plans. The focus is on small target volumes near radiation-sensitive organs in the ocular region, to evaluate the advantages of these techniques in treating skin cancer.
Methods: This retrospective observational analysis included patients who underwent skin cancer HDR-BT Freiburg flap treatment between 2019 and 2023.
Clin Oncol (R Coll Radiol)
December 2024
Department of Oncology, University College London Hospitals NHS Foundation Trust, 250 Euston Road, London, NW1 2PG, UK. Electronic address:
Aims: Brachytherapy is advantageous for localised rhabdomyosarcomas in children compared with external beam radiotherapy, sparing close organs at risk with highly conformal dosimetry. A methodology for planning and delivering fractionated high-dose-rate paediatric pelvic brachytherapy is detailed, and the dosimetric parameters are presented. This provides a practical template for radiotherapy departments with a similar patient cohort to implement this treatment technique.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!